Welcome to our dedicated page for MOBERG PHARMA AB PUBL news (Ticker: MBGPF), a resource for investors and traders seeking the latest updates and insights on MOBERG PHARMA AB PUBL stock.
Moberg Pharma AB (MBGPF) is a Swedish pharmaceutical innovator focused on advanced topical treatments for nail fungus (onychomycosis). This page aggregates official company announcements, clinical trial updates, and regulatory developments related to its flagship product MOB-015.
Investors and healthcare professionals will find timely updates on EU market expansions, clinical research outcomes, and strategic partnerships. Our curated news collection provides verified information about product approvals, scientific publications, and operational milestones without speculative commentary.
Key updates include progress on topical drug delivery systems, regulatory submissions, and financial performance reports. Bookmark this page for direct access to primary source materials that support informed analysis of Moberg Pharma's position in the dermatology sector.
Moberg Pharma announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in its North American phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The study, conducted at 33 centers in the US and Canada with 384 patients, showed that the shorter treatment regimen was insufficient compared to the daily dosing throughout treatment period approved in 13 EU countries.
Following these results and strategic considerations, Bayer Consumer Health has decided to stop the upcoming launch of MOB-015, leading to a mutual termination of the license agreement. Moberg Pharma will regain full rights for MOB-015 in EU while retaining previously paid milestone revenues. The company will shift focus to the European market, where MOB-015 (branded as Terclara®) is already successful in Sweden, growing the market by 44% and achieving 76% mycological cure with daily dosing.
FAQ
What is the current stock price of MOBERG PHARMA AB PUBL (MBGPF)?
What is the market cap of MOBERG PHARMA AB PUBL (MBGPF)?
